Framingham
Risk Calculator
Using Canadian Lipid Guidelines
References
2.
U.S.
Preventive Services Task Force. Aspirin for the Prevention of
Cardiovascular Disease: Clinical Summary. AHRQ Publication
No.09-05129-EF-3, March 2009. Agency for Healthcare Research and Quality,
Rockville, MD. [Online] Available at: http://www.ahrq.gov/clinic/uspstf09/aspirincvd/aspcvdsum.htm Accessed Jan 30, 2010.
3.
D’Agostino
RB, Vasan RS, Pensina MJ, et al. General
cardiovascular risk profile for use in primary care: the Framingham heart
study. Circulation 2008; 117: 743-753.
4.
deRuijter W,
Westendorp R, Assendelft W, et al. Use
of Framingham risk score and new biomarkers to predict cardiovascular mortality
in older people: population based observational cohort study. BMJ
2008;337:a3083 doi:10.1136/bmj.a3083
5.
Eichler K, Puhan MA,
Steurer J, Bachmann LM. Prediction of
first coronary events with the Framingham score: a systematic review. Am Heart J. 2007;153(5):722-31, 731.e1-8.
6.
Brindle
P, McConnachie A, Upton MN, et al. The
accuracy of the Framingham risk-score in different socioeconomic groups: a
prospective study. British J Gen Pract.
2005; 55: 838-845.
7.
Ridker
PM, Danielson E, Fonseca FA, et al.
Rosuvastatin to prevent vascular events in men and women with elevated
c-reactive protein. N Engl J Med 2008; 359: 2195-2207.
8.
Ridker
PM, Cook, NR, Lee I, et al. A randomized
trial of low-dose aspirin in the primary prevention of cardiovascular disease
in women. N Engl J Med 2005; 352:
1293-1304.
9.
Baigent C,
Antithrombotic Trialist’s Collaboration.
Aspirin in the primary and secondary prevention of vascular disease:
collaborative meta-analysis of individual participant data from randomised
trials. Lancet 2009; 373(9678):
1849-1860.
10.
Bayliss M, Ignaszewski
A. Does an Aspirin a day keep the doctor
away? Acetylsalicylic acid for the primary prevention of cardiovascular
disease. BC Medical J 2010; 52(6):
298-302.
11.
Ogawa H, Nakayama M,
Morimoto T, et al. Low-dose Aspirin for
primary prevention of atherosclerotic events in patients with type 2 diabetes:
a randomized controlled trial. JAMA
2008; 300(18): 2134-2141.
12.
De Berardis G, Sacco
M, Strippoli FM, et al. Aspirin for
primary prevention of cardiovascular events in people with diabetes:
meta-analysis of randomized controlled trials.
BMJ 2009; 339: b4531 doi:10.1136/bmj.b4531.
13. Nanchen D, et al.
Public
health impact of statin prescribing strategies based on JUPITER. Preventive Medicine 2011; 52: 159–163